PUMA BIOTECHNOLOGY INC (PBYI) — insider trading
Health Care · NASDAQ
PUMA BIOTECHNOLOGY INC (PBYI) has 23 reported SEC Form 4 insider transactions in our data, including 10 open-market sales among the most recent 23 (latest 2026-09-14).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | WILSON TROY EDWARD | Director | Open-market sale | 5,000 | $9.10 | $45.5K | Form 4 |
| 2026-09-14 | Cesano Alessandra | Director | Option exercise / conversion (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-09-14 | Cesano Alessandra | Director | Open-market sale | 62,150 | $9.12 | $567.0K | Form 4 |
| 2026-09-14 | Cesano Alessandra | Director | Option exercise / conversion | 50,000 | $2.93 | $146.5K | Form 4 |
| 2026-07-06 | NOUGUES MAXIMO F | Officer (Chief Financial Officer) | Open-market sale | 9,386 | $8.26 | $77.6K | Form 4 |
| 2026-07-06 | HUNT DOUGLAS M | Officer (See Remarks) | Open-market sale | 8,460 | $8.26 | $69.9K | Form 4 |
| 2026-07-06 | AUERBACH ALAN H | Director, Officer (President and CEO), 10% owner | Open-market sale | 44,058 | $8.26 | $364.1K | Form 4 |
| 2026-06-12 | Dorval Allison | Director | Open-market sale | 11,610 | $7.20 | $83.6K | Form 4 |
| 2026-06-12 | MOYES JAY M | Director | Open-market sale | 22,000 | $7.22 | $158.8K | Form 4 |
| 2026-06-12 | Senderowicz Adrian | Director | Open-market sale | 27,000 | $7.20 | $194.3K | Form 4 |
| 2026-06-12 | Stuglik Brian M | Director | Open-market sale | 8,100 | $7.20 | $58.3K | Form 4 |
| 2026-06-12 | WILSON TROY EDWARD | Director | Open-market sale | 10,800 | $7.20 | $77.7K | Form 4 |
| 2026-06-11 | Cesano Alessandra | Director | Grant / award / vesting | 27,000 | — | $0 | Form 4 |
| 2026-06-11 | Dorval Allison | Director | Grant / award / vesting | 27,000 | — | $0 | Form 4 |
| 2026-06-11 | MOYES JAY M | Director | Grant / award / vesting | 27,000 | — | $0 | Form 4 |
| 2026-06-11 | MILLER MICHAEL PATRICK | Director | Grant / award / vesting | 27,000 | — | $0 | Form 4 |
| 2026-06-11 | Senderowicz Adrian | Director | Grant / award / vesting | 27,000 | — | $0 | Form 4 |
| 2026-06-11 | Stuglik Brian M | Director | Grant / award / vesting | 27,000 | — | $0 | Form 4 |
| 2026-06-11 | WILSON TROY EDWARD | Director | Grant / award / vesting | 27,000 | — | $0 | Form 4 |
| 2026-02-18 | HUNT DOUGLAS M | Officer (See Remarks) | Grant / award / vesting (derivative) | 70,321 | — | $0 | Form 4 |
| 2026-02-18 | HUNT DOUGLAS M | Officer (See Remarks) | Grant / award / vesting | 49,394 | — | $0 | Form 4 |
| 2026-02-18 | AUERBACH ALAN H | Director, Officer (President and CEO), 10% owner | Grant / award / vesting (derivative) | 227,474 | — | $0 | Form 4 |
| 2026-02-18 | AUERBACH ALAN H | Director, Officer (President and CEO), 10% owner | Grant / award / vesting | 159,778 | — | $0 | Form 4 |
Ask the chat about PBYI's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: PUMA BIOTECHNOLOGY INC (PBYI).
Last updated 2026-09-14 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.